title: [Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
abstract: We evaluated the safety and efficacy of capecitabine in 12 patients with anthracycline and/or taxane-resistant metastatic breast cancer on an outpatient basis. Their mean age was 57 years, and they previously received chemotherapy consisting of anthracycline in 7 cases, taxane in 12 and doxifluridine in 8. Their mean disease-free interval was 28.5 months, HER 2/neu and ER and/or PgR-positive was shown in 2 and 8 cases, respectively. The recurrent sites were lymph node in 9 cases, lung in 6, skin in 5, pleural effusion in 4, liver, bone and pleura in 3, brain and CBS in 2, and thyroid, ascites and pericardial effusion in one, respectively. The administration dose was 2,400 mg/day in 11 cases and 3,000 mg/day in one. Capecitabine was administered orally for 21 consecutive days followed by a one-week rest. The mean follow-up period was 6.5 months. The overall response rate was 18.2% in 11 cases, including 2 partial responses, 4 stable diseases and 5 progressive diseases. Clinical benefit was 36.4% including two long stable diseases. The mean time to treatment failure was 6.5 months. Adverse events included Hand-Foot Syndrome in 5 cases, nausea in 3, diarrhea, appetite loss and high fever in one, respectively. In two of them administration was discontinued due to adverse events. Capecitabine had satisfactory effects with tolerable adverse events for anthracycline- and/or taxane-resistant metastatic breast cancer.
authors.affiliation: Dept of Surgery II, Dokkyo University School of Medicine.
authors.forename: Nobumi
authors.initials: N
authors.lastname: Tagaya
authors.forename: Aya
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Shouzou
authors.initials: S
authors.lastname: Mori
authors.forename: Masashi
authors.initials: M
authors.lastname: Tachibana
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kakihara
authors.forename: Kiyoshige
authors.initials: K
authors.lastname: Hamada
authors.forename: Norio
authors.initials: N
authors.lastname: Suzuki
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kubota
mesh_terms: D000284:Administration, Oral; D018943:Anthracyclines / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008875:Middle Aged; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D018943:Anthracyclines; D000964:Antimetabolites, Antineoplastic; D043823:Taxoids; D005467:Floxuridine; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil; C025034:doxifluridine